These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36648355)

  • 1. Circulating tumor DNA-guided minimal residual disease assessment in colorectal cancer.
    Chakrabarti S; Mahipal A
    Pharmacogenomics; 2023 Jan; 24(1):1-4. PubMed ID: 36648355
    [No Abstract]   [Full Text] [Related]  

  • 2. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
    Bent A; Raghavan S; Dasari A; Kopetz S
    Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 4. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.
    Nakamura Y; Tsukada Y; Matsuhashi N; Murano T; Shiozawa M; Takahashi Y; Oki E; Goto M; Kagawa Y; Kanazawa A; Ohta T; Ouchi A; Bando H; Uchigata H; Notake C; Ikematsu H; Yoshino T
    Clin Cancer Res; 2024 Oct; 30(19):4377-4387. PubMed ID: 39110016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.
    Malla M; Parikh AR
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):583-601. PubMed ID: 35577710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in the application of minimal residual disease in non-metastatic colorectal cancer].
    Cao D; Wang F; Zhang RX; Wei B; He MY; Peng JJ; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):749-755. PubMed ID: 39004992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Circulating Tumor DNA to Monitor Minimal Residual Disease Among Patients With Colorectal Cancer.
    Chitwood H; Myers A
    Clin J Oncol Nurs; 2023 Jul; 27(4):369-374. PubMed ID: 37677775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
    Chen Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
    Dasari A; Morris VK; Allegra CJ; Atreya C; Benson AB; Boland P; Chung K; Copur MS; Corcoran RB; Deming DA; Dwyer A; Diehn M; Eng C; George TJ; Gollub MJ; Goodwin RA; Hamilton SR; Hechtman JF; Hochster H; Hong TS; Innocenti F; Iqbal A; Jacobs SA; Kennecke HF; Lee JJ; Lieu CH; Lenz HJ; Lindwasser OW; Montagut C; Odisio B; Ou FS; Porter L; Raghav K; Schrag D; Scott AJ; Shi Q; Strickler JH; Venook A; Yaeger R; Yothers G; You YN; Zell JA; Kopetz S
    Nat Rev Clin Oncol; 2020 Dec; 17(12):757-770. PubMed ID: 32632268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.
    Sato S; Nakamura Y; Oki E; Yoshino T
    Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utilization of circulating tumor DNA to predict the risk and location of relapse after curative-intent local therapy in oligometastatic colorectal cancer.
    Radomski SN; Ali S; Lafaro KJ; Shubert C; Hidalgo M; Chung H; Christenson ES
    J Gastrointest Surg; 2024 Apr; 28(4):534-537. PubMed ID: 38583907
    [No Abstract]   [Full Text] [Related]  

  • 16. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
    Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
    Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
    Naidoo M; Piercey O; Tie J
    Curr Oncol Rep; 2021 Nov; 23(12):140. PubMed ID: 34735665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?
    Andersen CL; Heitzer E
    Cancer Cell; 2022 Sep; 40(9):911-913. PubMed ID: 36055230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
    Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
    Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.